Skip to content

Effect of Consumption of Supplements and Enriched Olive Paste on Bone Metabolism Indices

Effect of the Consumption of Vitamin C, D3, Ca Supplements and Olive Paste Enriched With Mountain Tea on Bone Metabolism Indices in Postmenopausal Women With Increased Osteoporosis' Risk: A Prospective Interventional Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06135831
Acronym
Osteoporosis
Enrollment
115
Registered
2023-11-18
Start date
2019-03-15
Completion date
2021-06-30
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia or Osteoporosis

Keywords

postmenopausal, osteopenia, osteoporosis, supplements, functional olive paste

Brief summary

It was a prospective randomized controlled trial. A sample of 115 apparently healthy post-menopausal women(45 -75 years of age) randomized into four groups and received supplements of Ca, Vitamin D and Mg with or without enriched olive paste and with or without Vitamin C. Changes in calciregulatory hormone were evaluated at the beginning of the study, at 5 and 12 months . Blood levels of vitamin D, vitamin C, Ca, Mg, the lipid profile, anthropometric indices and bone density were assessed at the beginning and at the end of the study.

Detailed description

: It was a prospective randomized controlled trial. A sample of 115 apparently healthy post-menopausal women(45 -75 years of age) randomized into four groups: (I) nutritional intervention group(n=40) received daily 1000mg vitamin C, 500mg vitamin D3, 500mg calcium(Ca) and 300mg magnesium (Mg); (II) control group(n=42) received daily 500mg vitamin D3, 500mg Ca and 300mg Mg; (III) nutritional intervention group (n=18) received daily 150mg bisphosphonates, 500mg vitamin D3, 500mg Ca and 300mg Mg; and (IV) nutritional intervention group (n=15) received daily about 364 mg polyphenols via an innovative functional food (50g olive paste enriched with mountain tea extract) along with 500mg vitamin D3, 500mg Ca and 300mg Mg. Groups I -III received supplementation for a year whereas group IV for 5 months. Changes in calciregulatory hormone parathormone (PTH) were evaluated at the beginning of the study as well as at 5 and 12 months intervals. Blood levels of vitamin D, vitamin C, Ca, Mg and the lipid profile were assessed at the beginning and at the end of the study. Anthropometric indices (weight, body fat(Kg), Body Mass Index(BMI) and bone mineral density(BMD) were evaluated at the beginning and at the end of the study.

Interventions

OTHERFunctional olive paste

Homogenised olive pastes, enriched with mountain tea, were supplied by two ac-credited Greek olive oil and olive products companies, Arcadian Taste and GAEA. The fortified olive pastes, contained 7.5 g of extra virgin olive oil, 3.75 g of salt, 3.75 g of grated oregano, 3.75 g of grated pepper, 7.5 g of grated garlic, 6.25 g of orange juice, 65 g of Kala-mon olives without seeds and 3 g of mountain tea and weighted 100 gr per portion size, as well.

OTHERCalciovitmag (CDCaMg)

Vitamin C (1000 mg), vitamin D3 (500 mg), Calcium (Ca) (500 mg ) and Magnesium (Mg) (300 mg)/day

OTHERPhosporovitmag (PDCaMg)

Bisphosphonates (150 mg), vitamin D3 (500 mg), Ca (500 mg ) and Mg (300 mg)/daily

OTHERControl

Vitamin D3 (500 mg), Calcium (500 mg) and Magnesium (300 mg)/daily

Sponsors

University of the Aegean
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

It was a single blinded nutritional intervention, where only participants didn't know in which group was recruited.

Intervention model description

Each study arm received different supplementation.

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 45 to 75 years old * Screening for osteoporosis (t-score ≤ - 1 normal bone density, t-score ≤ 2.5 osteoporosis ) and osteopenia of the femur strength or spine (t-score between -1 and -2.5 )

Exclusion criteria

* Age \> 75 y.o. and \<45 y.o * Diagnosed with chronic diseases including cancer, diabetes, coronary heart disease and stroke

Design outcomes

Primary

MeasureTime frameDescription
Changes in calciregulatory hormone parathormone12 monthsChanges in calciregulatory hormone parathormone (PTH) at baseline, 5 and 12 months

Secondary

MeasureTime frameDescription
Changes in Calcium12 monthsChanges in Calcium at baseline and 12 months
Changes in Vitamin C12 monthsChanges in Vitamin C at baseline and 12 months
Changes in Magnesium12 monthsChanges in Magnesium at baseline and 12 months
Changes in Vitamin D12 monthsChanges in Vitamin D at baseline and 12 months
Changes in body weight, body mass index and body fat12 monthsChanges in body weight, body mass index and body fat at baseline and 12 months
Changes in Bone Mineral Density12 monthsChanges in Bone Mineral Density at baseline and 12 months
Changes in serum lipids12 monthsChanges in serum lipids at baseline and 12 months

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026